12:30 PM Registration
1:00 PM Welcome and Introduction
Srdan Verstovsek, MD, PhD, Program Director and Moderator
1:10 PM Case Discussions
- Classifying PV and MF: Distinguishing From Reactive Conditions and Discriminating Among MPNs
- Aggressive PV: Characteristics, Clinical Implications, and Treatment Considerations
- Second-line Therapies in PV: Determining the Optimal Strategy After Hydroxyurea Failure
- Optimizing Therapeutic Strategies for Patients With MF
- Building Better Combination Strategies in MF Treatment
For each case presented, the faculty will discuss available clinical data and their use in guiding treatment decisions.
3:30 PM Panel Discussion of a 2018 Treatment Algorithm for PV and MF
3:45 PM Final Thoughts and Audience Question and Answer Session
4:00 PM Adjournment
Date / Time
Srdan Verstovsek, MD, PhD
Division of Cancer Medicine
Department of Leukemia
The University of Texas M. D. Anderson Cancer Center
John Mascarenhas, MD
Associate Professor of Medicine
Tisch Cancer Institute
Icahn School of Medicine at Mount Sinai
New York, New York
Raajit K. Rampal, MD, PhD
Assistant Attending Physician
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York
Brady L. Stein, MD, MHS
Assistant Professor of Medicine
Northwestern University Feinberg School of Medicine
The primary purpose of this program is to provide clinicians with expert recommendations and insights to address current clinical diagnostic and management issues and challenges for patients with polycythemia vera and myelofibrosis. To accomplish this, the program will emphasize interactive case presentations with expert panel discussions and debate.
The goal of this activity is to improve participants’ competence in and performance at treating patients with polycythemia vera and myelofibrosis.
This program is intended for physicians and other healthcare providers who care for patients with polycythemia vera and myelofibrosis.
- Utilize clinical evidence and updated multiparameter criteria to help to distinguish PV and MF from reactive conditions and discriminating among them the Philadelphia chromosome–negative MPNs
- Discuss the impact of mutational profiling in the management of PV and MF
- Tailor therapy for patients with high-risk or aggressive PV using evidence-based guidance on best practices, safety considerations, available research data
- Develop a plan to select second-line therapies for patients with PV who are refractory/relapsed to first-line agents
- Critically interpret most recent results of clinical trials to optimize treatment/management of MF in the era of JAK inhibition
- Evaluate the clinical data on promising agents and combination regimens likely to improve outcomes for patients with PV and MF
- Identify ongoing trials for the treatment of PV to aid referral of patients for study participation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and Clinical Care Options, LLC. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.
Postgraduate Institute for Medicine designates this live activity for a maximum of 3.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.